Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Current Leases (2021 - 2026)

Oric Pharmaceuticals filings provide 6 years of Current Leases readings, the most recent being $3.3 million for Q1 2026.

  • Quarterly Current Leases rose 2.58% to $3.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Mar 2026, up 2.58% year-over-year, with the annual reading at $3.3 million for FY2025, 4.62% up from the prior year.
  • Current Leases hit $3.3 million in Q1 2026 for Oric Pharmaceuticals, down from $3.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.3 million in Q4 2025 and bottomed at $2.0 million in Q1 2022.
  • Average Current Leases over 5 years is $2.9 million, with a median of $2.8 million recorded in 2024.
  • The largest annual shift saw Current Leases skyrocketed 61.9% in 2022 before it grew 2.44% in 2024.
  • Oric Pharmaceuticals' Current Leases stood at $2.7 million in 2022, then increased by 3.5% to $2.8 million in 2023, then rose by 15.66% to $3.2 million in 2024, then grew by 4.62% to $3.3 million in 2025, then fell by 1.02% to $3.3 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Current Leases are $3.3 million (Q1 2026), $3.3 million (Q4 2025), and $3.3 million (Q3 2025).